bpc 157 fda warning news 2025 october moves toward easing restrictions on certain peptides Compounded "semaglutide" is not FDA-approved

Annual Review of Biophysics, 40, 169

Pharmacies are regulated at the state level and are generally not subject to the same scrutiny as companies overseen by FDA

Over 80% of BPC-157 research comes from one lab whose leader also owns the company holding the patents

Theres no shame in asking for help

Who Each Format May Suit: Oral BPC-157 May Be Preferable For: Individuals needle-averse or injection-hesitant Those seeking convenient once-daily supplementation Peptide therapy beginners exploring the category People with active travel schedules Those primarily interested in gut health applications (topical GI contact) Individuals preferring established supplement companies over gray-market sources Injectable BPC-157 May Be Preferable For: Experienced peptide users comfortable with injection protocols Those working with knowledgeable practitioners providing dosing guidance Individuals seeking maximum potential bioavailability People with access to quality compounding pharmacies Users able to maintain twice-daily injection schedules Neither format is objectively superior for all users